Phase II study of glofitamab in patients with R/R LBCL

Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCLПодробнее

Phase II study of epcoritamab in R/R LBCLПодробнее

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCLПодробнее

Phase I study of costimulatory bispecific antibody RO7227166 combined with glofitamab in R/R B-NHLПодробнее

Glofitamab as a single agent in heavily pretreated patients with DLBCLПодробнее

A Phase I/II trial of glofitamab monotherapy in R/R MCLПодробнее

Update on Phase I/II study of glofitamab monotherapy in R/R MCLПодробнее

Insights into Phase I/II study assessing fixed-duration glofitamab treatment for R/R LBCLПодробнее

Glofitamab plus R-CHOP in patients with high-risk LBCL: a Phase II trialПодробнее

Phase II study of acalabrutinib plus RICE in R/R DLBCLПодробнее

What is the rationale behind step-up dosing of glofitamab in patients with MCL?Подробнее

Extended follow-up of glofitamab monotherapy in R/R LBCL: durability of CR and likelihood of CRSПодробнее

The benefits of glofitamab in R/R DLBCL post-CAR-T therapyПодробнее

Impact of TMTV on PFS following glofitamab treatment in R/R DLBCLПодробнее

Michael Dickinson, MBBS, DMedSc, on a Phase Ib Trial of Glofitamab Plus Pola-R-CHP in DLBCLПодробнее

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & moreПодробнее

Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapyПодробнее

Glofitamab: a valuable agent for the treatment of patients with R/R mantle cell lymphomaПодробнее

Updated efficacy data on glofitamab step-up dosing in NHLПодробнее